Case Overview: A new class action lawsuit alleges that Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic caused a patient to suffer severe vision loss, claiming the pharmaceutical company failed to adequately warn consumers and prescribing physicians of this risk.

Consumers Affected: Patients who were prescribed or used Ozempic (semaglutide) and experienced vision-related complications

Court: To be confirmed upon case filing details

Novo Nordisk Faces New Class Action Alleging Ozempic Caused Severe Vision Loss

A new class action lawsuit targeting Novo Nordisk claims the company's widely prescribed drug Ozempic led to serious vision loss in at least one patient — and that the pharmaceutical giant failed to warn the public about that risk. According to a recent report on the class action filing, the lawsuit adds to a growing wave of litigation challenging what Ozempic's manufacturer knew about the drug's potential side effects and when they knew it.

Lawsuit Claims Novo Nordisk Failed to Warn of Vision Risks

At the center of the complaint is an allegation that Novo Nordisk knew — or should have known — that Ozempic carried a risk of vision impairment but failed to include adequate warnings on the drug's labeling or communicate those risks to prescribing physicians.

The lawsuit alleges that the plaintiff suffered severe vision loss following use of the drug, and that this harm was a foreseeable consequence of taking semaglutide, Ozempic's active ingredient. According to the complaint, had the plaintiff been properly warned of this potential side effect, they may have made a different decision about whether to use the medication.

This type of claim — known in pharmaceutical litigation as a failure to warn — is among the most common legal theories in drug injury cases. It holds that manufacturers have a duty to disclose known risks, and that failing to do so leaves patients unable to make fully informed decisions about their care.

Ozempic's Rise and the Legal Scrutiny That Followed

Ozempic was originally approved by the U.S. Food and Drug Administration to improve blood sugar control in adults with type 2 diabetes. Its active ingredient, semaglutide, belongs to a class of drugs known as GLP-1 receptor agonists, which work by mimicking a hormone that regulates blood sugar and appetite. The drug surged in popularity in recent years as it gained widespread attention for significant weight-loss effects — including off-label use among patients without diabetes.

That rapid adoption has come with intensifying legal scrutiny. This lawsuit is described as another Novo Nordisk class action, suggesting the company is now contending with multiple simultaneous legal challenges related to Ozempic's side effects.

Vision Loss as an Emerging Safety Concern

The alleged link between semaglutide and vision problems has drawn attention in recent months. A study published in 2024 in JAMA Ophthalmology found a potential association between semaglutide use and a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and permanent vision loss. Researchers emphasized that the study demonstrated an association, not a definitive causal link, and called for further investigation.

The lawsuit's allegations reflect this emerging area of scientific concern. According to the complaint, the vision-related risks associated with Ozempic were not adequately communicated to patients — a claim that, if proven, could have significant implications for how GLP-1 drugs are labeled and prescribed going forward.

A Pattern of Ozempic Litigation

This filing is the latest in a series of class action lawsuits and individual injury claims targeting Ozempic and related semaglutide-based drugs. Earlier litigation has focused on other alleged side effects, including severe gastroparesis — a form of stomach paralysis — with those cases consolidated into a federal Multi-District Litigation (MDL) proceeding. The addition of vision loss claims signals that plaintiffs' attorneys are continuing to identify and pursue new alleged harms connected to the drug's widespread use.

Novo Nordisk has not yet publicly responded to this specific lawsuit. The company has previously defended its products, pointing to the FDA's approval process and existing drug labeling as evidence of appropriate disclosure.

Related Cases

• Ozempic Linked to Stomach Paralysis in Growing Number of Lawsuits
• Wegovy Faces Similar GLP-1 Litigation Over Severe Side Effects
• FDA Issues New Guidance on GLP-1 Drug Labeling Requirements

Lawsuit: To be updated with full plaintiff and defendant case caption

Case Number: To be confirmed upon public court record availability

Court: To be confirmed

Plaintiffs' Attorney(s): To be confirmed

This article is for informational purposes only and does not constitute legal or medical advice. Consult your doctor before making any changes to your medication.

Have you or someone you know experienced vision changes or other unexpected side effects while taking Ozempic? Share your experience in the comments below.